In January 2020, a phase II study to evaluate AB-928 in combination with the anti-PD-1 zimberelimab or with AB-154 (a humanized mAb targeting human T cell immune-receptor with Ig and ITIM domains (TIGIT)) in participants with PD-L1-positive NSCLC, was started (NCT04262856). Here, CD274 is linked to non-small cell lung carcinoma.